Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532.
Publication
, Journal Article
Perry, MC; Ihde, DC; Herndon, JE; Grossbard, ML; Grethein, SJ; Atkins, JN; Vokes, EE; Green, MR
Published in: Lung Cancer
April 2000
In order to explore non-cisplatin containing regimens for advanced non-small cell lung cancer, Cancer and Leukemia Group B conducted a randomized Phase-II study of two novel combinations, paclitaxel/ifosfamide and vinorelbine/ifosfamide. Both regimens were active with a 38% response rate (95% CI: 24%, 53%) and 31% (95% CI: 18%, 47%), respectively. Median survivals were 8.5 and 7.4 months. Toxicity, mostly neutropenia, was acceptable. These two combinations establish a 'proof of principle' that non-cisplatin containing regimens also have activity in this setting.
Duke Scholars
Published In
Lung Cancer
DOI
ISSN
0169-5002
Publication Date
April 2000
Volume
28
Issue
1
Start / End Page
63 / 68
Location
Ireland
Related Subject Headings
- Vinorelbine
- Vinblastine
- Treatment Outcome
- Survival Rate
- Paclitaxel
- Oncology & Carcinogenesis
- Neoplasm Staging
- Middle Aged
- Male
- Lung Neoplasms
Citation
APA
Chicago
ICMJE
MLA
NLM
Perry, M. C., Ihde, D. C., Herndon, J. E., Grossbard, M. L., Grethein, S. J., Atkins, J. N., … Green, M. R. (2000). Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532. Lung Cancer, 28(1), 63–68. https://doi.org/10.1016/s0169-5002(99)00129-4
Perry, M. C., D. C. Ihde, J. E. Herndon, M. L. Grossbard, S. J. Grethein, J. N. Atkins, E. E. Vokes, and M. R. Green. “Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532.” Lung Cancer 28, no. 1 (April 2000): 63–68. https://doi.org/10.1016/s0169-5002(99)00129-4.
Perry MC, Ihde DC, Herndon JE, Grossbard ML, Grethein SJ, Atkins JN, et al. Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532. Lung Cancer. 2000 Apr;28(1):63–8.
Perry, M. C., et al. “Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532.” Lung Cancer, vol. 28, no. 1, Apr. 2000, pp. 63–68. Pubmed, doi:10.1016/s0169-5002(99)00129-4.
Perry MC, Ihde DC, Herndon JE, Grossbard ML, Grethein SJ, Atkins JN, Vokes EE, Green MR. Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532. Lung Cancer. 2000 Apr;28(1):63–68.
Published In
Lung Cancer
DOI
ISSN
0169-5002
Publication Date
April 2000
Volume
28
Issue
1
Start / End Page
63 / 68
Location
Ireland
Related Subject Headings
- Vinorelbine
- Vinblastine
- Treatment Outcome
- Survival Rate
- Paclitaxel
- Oncology & Carcinogenesis
- Neoplasm Staging
- Middle Aged
- Male
- Lung Neoplasms